Corporate
May 23, 2013
Latham guides $700 million Scandinavian pharmaceutical deal
Latham & Watkins LLP advised Danish investment firm Novo A/S in its purchase of Norwegian pharmaceutical company Xellia Pharmaceuticals AS for $700 million.
Daily Journal Staff Writer
Latham & Watkins LLP attorneys in California and England guided a $700 million all-Scandinavian pharmaceutical acquisition, announced Tuesday.
Latham advised Danish investment firm Novo A/S, a holding company of the Novo Group, in its purchase of Norwegian pharmaceutical company Xellia Pharmaceuticals AS from London-based private equity group 3i Group PLC and other shareholders.
Xelli...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In